In hospital risk factors for acute kidney injury and its burden in patients with Sars-Cov-2 infection : a longitudinal multinational study
© 2022. The Author(s)..
Acute kidney injury (AKI) is associated with increased mortality in most critical settings. However, it is unclear whether its mild form (i.e. AKI stage 1) is associated with increased mortality also in non-critical settings. Here we conducted an international study in patients hospitalized with SARS-CoV-2 infection aiming 1. to estimate the incidence of AKI at each stage and its impact on mortality 2. to identify AKI risk factors at admission (susceptibility) and during hospitalization (exposures) and factors contributing to AKI-associated mortality. We included 939 patients from medical departments in Moscow (Russia) and Padua (Italy). In-hospital AKI onset was identified in 140 (14.9%) patients, mainly with stage 1 (65%). Mortality was remarkably higher in patients with AKI compared to those without AKI (55 [39.3%] vs. 34 [4.3%], respectively). Such association remained significant after adjustment for other clinical conditions at admission (relative risk [RR] 5.6; CI 3.5- 8.8) or restricting to AKI stage 1 (RR 3.2; CI 1.8-5.5) or to subjects with AKI onset preceding deterioration of clinical conditions. After hospital admission, worsening of hypoxic damage, inflammation, hyperglycemia, and coagulopathy were identified as hospital-acquired risk factors predicting AKI onset. Following AKI onset, the AKI-associated worsening of respiratory function was identified as the main contributor to AKI-induced increase in mortality risk. In conclusion, AKI is a common complication of Sars-CoV2 infection in non-intensive care settings where it markedly increases mortality risk also at stage 1. The identification of hospital-acquired risk factors and exposures might help prevention of AKI onset and of its complications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Scientific reports - 12(2022), 1 vom: 02. März, Seite 3474 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morieri, Mario Luca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 14.03.2022 Date Revised 14.03.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-022-07490-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337681341 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337681341 | ||
| 003 | DE-627 | ||
| 005 | 20231226204315.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-022-07490-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1125.xml |
| 035 | |a (DE-627)NLM337681341 | ||
| 035 | |a (NLM)35236891 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morieri, Mario Luca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In hospital risk factors for acute kidney injury and its burden in patients with Sars-Cov-2 infection |b a longitudinal multinational study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2022 | ||
| 500 | |a Date Revised 14.03.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Acute kidney injury (AKI) is associated with increased mortality in most critical settings. However, it is unclear whether its mild form (i.e. AKI stage 1) is associated with increased mortality also in non-critical settings. Here we conducted an international study in patients hospitalized with SARS-CoV-2 infection aiming 1. to estimate the incidence of AKI at each stage and its impact on mortality 2. to identify AKI risk factors at admission (susceptibility) and during hospitalization (exposures) and factors contributing to AKI-associated mortality. We included 939 patients from medical departments in Moscow (Russia) and Padua (Italy). In-hospital AKI onset was identified in 140 (14.9%) patients, mainly with stage 1 (65%). Mortality was remarkably higher in patients with AKI compared to those without AKI (55 [39.3%] vs. 34 [4.3%], respectively). Such association remained significant after adjustment for other clinical conditions at admission (relative risk [RR] 5.6; CI 3.5- 8.8) or restricting to AKI stage 1 (RR 3.2; CI 1.8-5.5) or to subjects with AKI onset preceding deterioration of clinical conditions. After hospital admission, worsening of hypoxic damage, inflammation, hyperglycemia, and coagulopathy were identified as hospital-acquired risk factors predicting AKI onset. Following AKI onset, the AKI-associated worsening of respiratory function was identified as the main contributor to AKI-induced increase in mortality risk. In conclusion, AKI is a common complication of Sars-CoV2 infection in non-intensive care settings where it markedly increases mortality risk also at stage 1. The identification of hospital-acquired risk factors and exposures might help prevention of AKI onset and of its complications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Ronco, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Avogaro, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Farnia, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Shestakova, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Zaytseva, Natalya |e verfasserin |4 aut | |
| 700 | 1 | |a Mokrysheva, Natalya |e verfasserin |4 aut | |
| 700 | 1 | |a Akulkina, Larisa |e verfasserin |4 aut | |
| 700 | 1 | |a Shepalina, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Brovko, Michail |e verfasserin |4 aut | |
| 700 | 1 | |a Moiseev, Sergey |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzocut, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Vianello, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Cattellan, Anna Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Vedovato, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Fadini, Gian Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Vettor, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Fioretto, Paola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 12(2022), 1 vom: 02. März, Seite 3474 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:1 |g day:02 |g month:03 |g pages:3474 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-022-07490-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 1 |b 02 |c 03 |h 3474 | ||